BioCryst Pharmaceuticals, Inc. (BCRX) Position Reduced by Royce & Associates LP
Royce & Associates LP lessened its stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 41.1% in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 84,855 shares of the biotechnology company’s stock after selling 59,145 shares during the quarter. Royce & Associates LP owned approximately 0.08% of BioCryst Pharmaceuticals worth $685,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors also recently modified their holdings of the company. American International Group Inc. grew its holdings in shares of BioCryst Pharmaceuticals by 12.8% during the third quarter. American International Group Inc. now owns 72,390 shares of the biotechnology company’s stock worth $552,000 after buying an additional 8,236 shares in the last quarter. Teachers Advisors LLC grew its holdings in shares of BioCryst Pharmaceuticals by 4.1% during the third quarter. Teachers Advisors LLC now owns 294,786 shares of the biotechnology company’s stock worth $2,249,000 after buying an additional 11,682 shares in the last quarter. Bank of New York Mellon Corp grew its holdings in shares of BioCryst Pharmaceuticals by 3.1% during the third quarter. Bank of New York Mellon Corp now owns 420,825 shares of the biotechnology company’s stock worth $3,211,000 after buying an additional 12,544 shares in the last quarter. Dynamic Technology Lab Private Ltd purchased a new stake in shares of BioCryst Pharmaceuticals during the third quarter worth $122,000. Finally, Northern Trust Corp grew its holdings in shares of BioCryst Pharmaceuticals by 2.2% during the second quarter. Northern Trust Corp now owns 1,214,561 shares of the biotechnology company’s stock worth $6,960,000 after buying an additional 25,685 shares in the last quarter. 92.34% of the stock is owned by institutional investors.
In other BioCryst Pharmaceuticals news, CFO Thomas R. Staab II sold 5,000 shares of the company’s stock in a transaction dated Monday, January 28th. The shares were sold at an average price of $9.85, for a total value of $49,250.00. Following the transaction, the chief financial officer now owns 133,426 shares of the company’s stock, valued at $1,314,246.10. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, VP Lynne Powell sold 12,000 shares of the company’s stock in a transaction dated Monday, January 28th. The shares were sold at an average price of $9.75, for a total transaction of $117,000.00. Following the completion of the transaction, the vice president now directly owns 6,000 shares in the company, valued at approximately $58,500. The disclosure for this sale can be found here. Insiders sold 49,488 shares of company stock worth $434,962 in the last ninety days. 4.50% of the stock is currently owned by corporate insiders.
BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its quarterly earnings results on Monday, March 4th. The biotechnology company reported ($0.25) earnings per share for the quarter, beating the consensus estimate of ($0.26) by $0.01. BioCryst Pharmaceuticals had a negative net margin of 490.25% and a negative return on equity of 167.73%. The firm had revenue of $2.73 million for the quarter, compared to analysts’ expectations of $2.39 million. As a group, analysts forecast that BioCryst Pharmaceuticals, Inc. will post -1.19 earnings per share for the current year.
A number of equities research analysts have recently issued reports on the stock. Royal Bank of Canada upped their target price on shares of BioCryst Pharmaceuticals to $16.00 and gave the stock a “positive” rating in a report on Tuesday, December 4th. Zacks Investment Research lowered shares of BioCryst Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, March 11th. BidaskClub cut shares of BioCryst Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Thursday, January 31st. Finally, Piper Jaffray Companies began coverage on shares of BioCryst Pharmaceuticals in a research report on Friday, November 16th. They set an “overweight” rating and a $15.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $12.18.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals, Inc, a biotechnology company, designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases. The company markets peramivir, an intravenous neuraminidase inhibitor, which is approved for uncomplicated seasonal and acute influenza in the United States and Canada under the name RAPIVAB, in Japan and Taiwan as RAPIACTA, and in Korea as PERAMIFLU; and Mundesine, an oral purine nucleoside phosphorylase inhibitor to treat cancer in Japan.
See Also: Gap Up Stocks
Want to see what other hedge funds are holding BCRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX).
Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.